logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
I

Ingrid Boere

erasmus mc cancer institute
H指数:29
被引数:6,133

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tumor-specific super-enhancer drives overexpression of EVI1/MECOM in ovarian cancer

肿瘤特异性超级增强子驱动卵巢癌中<em>EVI1/MECOM</em>的过表达

Neoplasia
IF7.7
2026-10-120
OAAI
Sabrina Kruse; Sandra Kiehlmeier; Jagoda Mika; Marije Havermans; Roger Mulet-Lazaro; Kateřina Vašíčková; Mieke Timmermans; Stanley van Herk; Carl Herrmann; Andres Quintero; H. Berna Beverloo; Maurice Jansen; Floris H. Groenendijk; Ingrid Boere; John W.M. Martens; Ruud Delwel; Stefan Gröschel; Claudia Scholl; Stefan Fröhling; Leonie Smeenk
PARP-inhibitor response evaluation in recurrent epithelial ovarian cancer using circulating tumor DNA and functional HRD testing

利用循环肿瘤DNA和功能性HRD检测评估复发性上皮性卵巢癌的PARP抑制剂应答

International Journal of Gynecological Cancer
IF4.7
2026-10-010
OA
M. Vegter; L.M. van Wijk; C.J.H. Kramer; M. Jalving; T. Bosse; D.C. van Gent; S. Gelpke-Vermeulen; C.M. Beaufort; M.A.T.M van Vugt; T.G. Meijer; H.J. van Beekhuizen; M.P.H.M Jansen; M.P.G. Vreeswijk; I.A. Boere; J.R. Kroep
Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy

聚腺苷二磷酸核糖聚合酶抑制剂尼拉帕利维持治疗接受多斯塔利姆单抗联合化疗的原发进展或复发性子宫内膜癌患者

International Journal of Gynecological Cancer
IF4.7
2026-06-060
PRE
Matthew A. Powell; Sharad Ghamande; Lars C. Hanker; Destin Black; Nicoline Raaschou-Jensen; Lucy Gilbert; David Cibula; Angeles Alvarez Secord; Ana Oaknin; Robert W. Holloway; Hanne F. Mathiesen; Joseph Buscema; Rebecca Kristeleit; Sudarshan Sharma; Ingrid A. Boere; Brian Slomovitz; Christine Gennigens; Robert L. Coleman; Florian Heitz; Joyce N. Barlin
Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trial

SOLO2试验中，BRCA突变铂敏感复发性浆液性卵巢癌患者接受奥拉帕利维持治疗后的不良事件特征

International Journal of Gynecological Cancer
IF4.7
2026-03-020
OAAI
Jonathan A. Ledermann; Alain Lortholary; Richard T. Penson; Rebecca Asher; Val Gebski; Diane Provencher; Ilan Bruchim; Tomasz Huzarski; Maria Pilar Barretina-Ginesta; Stefania Pipitone; Linda Mileshkin; Nicoletta Colombo; Tjoung-Won Park-Simon; Koji Matsumoto; Ingrid Boere; Olga Mikheeva; Jae-Weon Kim; Gustavo Girotto; Ignace Vergote; Dave Carter
Dynamic immune changes after bone marrow sparing VMAT in women with locally advanced cervical cancer treated with chemoradiotherapy
Clinical and Translational Radiation Oncology
IF2.7
2026-01-160
OAAI
Marij J.P. Welters; Sanne Boekestijn; Jan Willem M. Mens; Henrike Westerveld; Mila Donker; Laura A. Velema; Hélène van Meir; Mariëtte I.E. van Poelgeest; Judith R. Kroep; Ingrid A. Boere; Sander C. Kuipers; Jeremy Godart; Mischa S. Hoogeman; Hein Putter; Carien L. Creutzberg; Remi A. Nout; Sjoerd H. van der Burg; Stephanie M. de Boer; Anouk Corbeau
Outcomes for ER-positive CHEK2 c.1100delC breast cancer patients compared with breast cancer patients without the variant.

与无该变异的乳腺癌患者相比，ER阳性CHEK2 c.1100delC乳腺癌患者的结局。

The Breast
IF0
2025-11-240
OAAI
Maartje A.C. Schreurs; Muriel A. Adank; Bernadette A.M. Heemskerk-Gerritsen; Antoinette Hollestelle; Nyrée Smallenbroek; Christi J. van Asperen; Margreet G.E.M. Ausems; Irma van de Beek; Geertruida H. de Bock; Ingrid Boere; Liselotte P. van Hest; Kim J.A.F. van Kaam; Linda de Munck; Janet R. Vos; Agnes Jager; Marjanka K. Schmidt; Maartje J. Hooning
A plain language summary publication of patients’ survival with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel

一份关于接受多塔利单抗联合卡铂-紫杉醇治疗子宫内膜癌患者生存情况的通俗语言摘要出版物

Therapeutic Advances in Medical Oncology
IF4.2
2025-10-090
OA
Matthew A. Powell; Line Bjørge; Lyndsay Willmott; Zoltán Novák; Destin Black; Lucy Gilbert; Sudarshan Sharma; Giorgio Valabrega; Lisa M. Landrum; Martina Gropp-Meier; Ashley Stuckey; Ingrid Boere; Michael A. Gold; Yakir Segev; Sarah E. Gill; Christine Gennigens; Alexandra Sebastianelli; Mark S. Shahin; Bhavana Pothuri; Bradley J. Monk; Joseph Buscema; Robert L. Coleman; Brian M. Slomovitz; Kari L. Ring; Thomas J. Herzog; Morad Marco Balas; Matthew Grimshaw; Shadi Stevens; Dominic W. Lai; Carolyn McCourt; Mansoor Raza Mirza
Changes in bone marrow fat fraction and immune cell counts in women with cervical cancer treated with primary chemoradiotherapy

接受初始化放疗的宫颈癌女性患者骨髓脂肪分数和免疫细胞计数的变化

Radiotherapy and Oncology
IF5.3
2025-08-090
OAAI
A. Corbeau; E. Astreinidou; S.C. Kuipers; P.A. Wielopolski; W. Visser; J.W.M. Mens; H. Westerveld; M. Donker; L.A. Velema; J.R. Kroep; I.A. Boere; M.J.P. Welters; S.H. van der Burg; M.S. Hoogeman; H. Putter; J. Godart; U.A. van der Heide; C.L. Creutzberg; R.A. Nout; S.M. de Boer
APOLLO: neo-adjuvant pembrolizumab for primary vulvar squamous cell carcinoma—a multicenter, single-arm, phase II, clinical proof-of-concept study

APOLLO：原发性外阴鳞状细胞癌的新辅助帕博利珠单抗治疗——一项多中心、单臂、II期概念验证临床研究

International Journal of Gynecological Cancer
IF4.7
2025-04-170
OAAI
M.I.E. van Poelgeest; Kim E. Kortekaas; Helena C. van Doorn; Maaike Oonk; Hans W. Nijman; Ingrid Boere; Anneke L. Eerkens; Anna.K.L. Reyners; Patricia C. Ewing-Graham; Joost Bart; Tjalling Bosse; Marij.J.P. Welters; Judith R. Kroep; Sjoerd H. van der Burg
Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)

多塔利单抗联合化疗在dMMR/MSI-H原发性晚期或复发性子宫内膜癌患者中的有效性和安全性：一项III期、随机、安慰剂对照试验（ENGOT-EN6-NSGO/GOG-3031/RUBY）。

gynecologic oncology
IF4.1
2025-01-014
PRE
Powell, Matthew A.; Cibula, David; O'Malley, David M.; Boere, Ingrid; Shahin, Mark S.; Savarese, Antonella; Chase, Dana M.; Gilbert, Lucy; Black, Destin; Herrstedt, Jorn; Sharma, Sudarshan; Kommoss, Stefan; Gold, Michael A.; Thijs, Anna M.; Ring, Kari; Bolling, Magnus Frodin; Buscema, Joseph; Gill, Sarah E.; Nowicki, Paul; Nevadunsky, Nicole; Callahan, Michael; Willmott, Lyndsay; McCourt, Carolyn; Billingsley, Caroline; Ghamande, Sharad A.; He, Zangdong; Balas, Morad Marco; Stevens, Shadi; Fleming, Evelyn; Mirza, Mansoor Raza
Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel- paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial
ANNALS OF ONCOLOGY
IF65.4
2024-08-014
OA
Powell, M. A.; Bjorge, L.; Willmott, L.; Novak, Z.; Black, D.; Gilbert, L.; Sharma, S.; Valabrega, G.; Landrum, L. M.; Gropp-Meier, M.; Stuckey, A.; Boere, I.; Gold, M. A.; Segev, Y.; Gill, S. E.; Gennigens, C.; Sebastianelli, A.; Shahin, M. S.; Pothuri, B.; Monk, B. J.; Buscema, J.; Coleman, R. L.; Slomovitz, B. M.; Ring, K. L.; Herzog, T. J.; Balas, M. M.; Grimshaw, M.; Stevens, S.; Lai, D. W.; Mccourt, C.; Mirza, M. R.
A Plain Language Summary of Dostarlimab for primary advanced or recurrent endometrial cancer
FUTURE ONCOLOGY
IF2.6
2024-07-010
PRE
Mirza, Mansoor R.; Chase, Dana M.; Slomovitz, Brian M.; Christensen, Rene dePont; Novak, Zoltan; Black, Destin; Gilbert, Lucy; Sharma, Sudarshan; Valabrega, Giorgio; Landrum, Lisa M.; Hanker, Lars C.; Stuckey, Ashley; Boere, Ingrid; Gold, Michael A.; Auranen, Annika; Pothuri, Bhavana; Cibula, David; McCourt, Carolyn; Raspagliesi, Francesco; Shahin, Mark S.; Gill, Sarah E.; Monk, Bradley J.; Buscema, Joseph; Herzog, Thomas J.; Copeland, Larry J.; Tian, Min; He, Zangdong; Stevens, Shadi; Zografos, Eleftherios; Coleman, Robert L.; Powell, Matthew A.
Tropomyosin1 isoforms underlie epithelial to mesenchymal plasticity, metastatic dissemination, and resistance to chemotherapy in high-grade serous ovarian cancer
CELL DEATH AND DIFFERENTIATION
IF15.4
2024-02-162
OAAI
Xu, Tong; Verhagen, Mathijs P.; Teeuwssen, Miriam; Sun, Wenjie; Joosten, Rosalie; Sacchetti, Andrea; Ewing-Graham, Patricia C.; Jansen, Maurice P. H. M.; Boere, Ingrid A.; Bryce, Nicole S.; Zeng, Jun; Treutlein, Herbert R.; Hook, Jeff; Hardeman, Edna C.; Gunning, Peter W.; Fodde, Riccardo
Phenotype-guided targeted therapy based on functional signal transduction pathway activity in recurrent ovarian cancer patients: The STAPOVER study protocol

基于复发性卵巢癌患者功能性信号转导通路活性的表型指导靶向治疗: STAPOVER研究方案

HELIYON
IF3.6
2024-01-011
OAAI
van der Ploeg, Phyllis; Hendrikse, Cynthia SE.; Thijs, Anna MJ.; Westgeest, Hans M.; Smedts, Huberdina PM.; Vos, M. Caroline; Jalving, Mathilde; Lok, Christianne AR.; Boere, Ingrid A.; van Ham, Maaike APC.; Ottevanger, Petronella B.; Westermann, Anneke M.; Mom, Constantijne H.; Lalisang, Roy I.; Lambrechts, Sandrina; Bekkers, Ruud LM.; Piek, Jurgen MJ.

研究方向

暂未获取到该数据
K
Kristel Van Calsteren
H 指数:45论文数:317被引数:8,460
F
Frédéric Amant
H 指数:95论文数:1,230被引数:4.3万
H
Helena C. van Doorn
H 指数:37论文数:175被引数:4,804
R
Ron H.J. Mathijssen
H 指数:76论文数:888被引数:1.9万
M
M Halaška
H 指数:43论文数:339被引数:7,042
M
Mina Mhallem Gzirí
H 指数:29论文数:85被引数:4,020
L
Lucy Gilbert
H 指数:42论文数:297被引数:1.0万
P
Petronella B. Ottevanger
H 指数:43论文数:199被引数:9,496
C
Christianne Lok
H 指数:29论文数:181被引数:3,512
M
Mark S. Shahin
H 指数:30论文数:124被引数:6,025